arctigenin has been researched along with Neuroblastoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hao, H; Hu, Y; Kang, T; Liang, W; Ren, L; Sun, D; Wen, Q; Xia, Y; Yan, Y; Yang, J; Zhang, G; Zhang, N; Zhang, X; Zhao, D | 1 |
| Dou, D; Jia, D; Kang, T; Li, D; Liu, Q; Wang, X | 1 |
2 other study(ies) available for arctigenin and Neuroblastoma
| Article | Year |
|---|---|
Neuroprotective effect of arctigenin via upregulation of P-CREB in mouse primary neurons and human SH-SY5Y neuroblastoma cells.
Topics: Animals; Cell Survival; Cells, Cultured; Cyclic AMP Response Element-Binding Protein; Furans; Humans; Lignans; Mice; Neuroblastoma; Neuroprotective Agents; Phosphorylation; Tumor Cells, Cultured | 2013 |
Protective effect of arctigenin against MPP+ and MPTP-induced neurotoxicity.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Apoptosis; bcl-2-Associated X Protein; Behavior, Animal; Brain; Cell Line, Tumor; Cell Survival; Dopamine; Furans; gamma-Aminobutyric Acid; Humans; Lignans; Male; Membrane Potential, Mitochondrial; Mice; Mice, Inbred C57BL; MPTP Poisoning; Neuroblastoma; Neuroprotective Agents; Neurotoxicity Syndromes; Parkinson Disease | 2014 |